Evidence map›Paper›PMID 27111569›Full record

ArticleMolecular immunology2016

Identification of the gC1qR sites for the HIV-1 viral envelope protein gp41 and the HCV core protein: Implications in viral-specific pathogenesis and therapy.

Lina Pednekar, Alisa Valentino, Yan Ji, Nithin Tumma, Christopher Valentino, Adarsh Kadoor, Kinga K Hosszu, Mahalakshmi Ramadass, Richard R Kew, Uday Kishore and 2 more

Abstract read
In one paragraph

Article in Molecular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. SLE: Novel Postulates for Therapeutic Options.Frontiers in immunology · 2020
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Lina PednekarCenter for Infection, Immunity and Disease Mechanisms, Biosciences, Brunel University, Uxbridge, UB8 3PH London, UK; The Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
Alisa ValentinoThe Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
Yan JiThe Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
Nithin TummaThe Departments of Pathology, Stony Brook University, Stony Brook, NY 11794, United States.
Christopher ValentinoThe Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
Adarsh KadoorCenter for Infection, Immunity and Disease Mechanisms, Biosciences, Brunel University, Uxbridge, UB8 3PH London, UK; The Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States; The Departments of Pathology, Stony Brook University, Stony Brook, NY 11794, United States; The Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), United States; The Department of Pathology, Weill-Cornell Medical College, NY, NY 10065, United States.
Kinga K HosszuThe Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
Mahalakshmi RamadassThe Departments of Pathology, Stony Brook University, Stony Brook, NY 11794, United States.
Richard R KewThe Departments of Pathology, Stony Brook University, Stony Brook, NY 11794, United States.
Uday KishoreCenter for Infection, Immunity and Disease Mechanisms, Biosciences, Brunel University, Uxbridge, UB8 3PH London, UK.
Ellinor I B PeerschkeThe Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), United States; The Department of Pathology, Weill-Cornell Medical College, NY, NY 10065, United States.
Berhane GhebrehiwetThe Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States; The Departments of Pathology, Stony Brook University, Stony Brook, NY 11794, United States. Electronic address: Berhane.Ghebrehiwet@stonybrookmedicine.edu.
Stony Brook University · USMemorial Sloan Kettering Cancer Center · USBrunel University of London · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
gC1q-R/p33: structure function and role on inflammation.R01AI060866 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI GHEBREHIWET, BERHANE · 2006 to 2009
$1.2M
The role of C1q in regulation of monocyte to dendritic cell transitionR01AI084178 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI GHEBREHIWET, BERHANE · 2009 to 2010
$602k
NCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI060866NIAID NIH HHS R01 AI084178
6 · The paper itself

Abstract

A substantial body of evidence accumulated over the past 20 years supports the concept that gC1qR is a major pathogen-associated pattern recognition receptor (PRR). This conclusion is based on the fact that, a wide range of bacterial and viral ligands are able to exploit gC1qR to either suppress the host's immune response and thus enhance their survival, or to gain access into cells to initiate disease. Of the extensive array of viral ligands that have affinity for gC1qR, the HIV-1 envelope glycoprotein gp41, and the core protein of hepatitis C virus (HCV) are of major interest as they are known to contribute to the high morbidity and mortality caused by these pathogens. While the HCV core protein binds gC1qR and suppresses T cell proliferation resulting in a significantly diminished immune response, the gp41 employs gC1qR to induce the surface expression of the NK cell ligand, NKp44L, on uninfected CD4(+) T cells, thereby rendering them susceptible to autologous destruction by NKp44 receptor expressing NK cells. Because of the potential for the design of peptide-based or antibody-based therapeutic options, the present studies were undertaken to define the gC1qR interaction sites for these pathogen-associated molecular ligands. Employing a solid phase microplate-binding assay, we examined the binding of each viral ligand to wild type gC1qR and 11 gC1qR deletion mutants. The results obtained from these studies have identified two major HCV core protein sites on a domain of gC1qR comprising of residues 144-148 and 196-202. Domain 196-202 in turn, is located in the last half of the larger gC1qR segment encoded by exons IV-VI (residues 159-282), which was proposed previously to contain the site for HCV core protein. The major gC1qR site for gp41 on the other hand, was found to be in a highly conserved region encoded by exon IV and comprises of residues 174-180. Interestingly, gC1qR residues 174-180 also constitute the cell surface-binding site for soluble gC1qR (sgC1qR), which can bind to the cell surface in an autocrine/paracrine manner via surface expressed fibrinogen or other membrane molecules. The identification of the sites for these viral ligands should therefore provide additional targets for the design of peptide-based or antigen-based therapeutic strategies.

Indexed as

Binding SitesCarrier ProteinsCD4-Positive T-LymphocytesHIV Envelope Protein gp41HumansMitochondrial ProteinsMonocytesReceptors, Pattern RecognitionU937 CellsViral Core ProteinsC1QBP protein, humanCarrier Proteinsgp41 protein, Human immunodeficiency virus 1HIV Envelope Protein gp41Mitochondrial Proteinsnucleocapsid protein, Hepatitis C virusReceptors, Pattern RecognitionViral Core ProteinsgC1qRHepatitis C virusHIV-1 gp41PRR

Identifiers

PMID27111569
PMCPMC4987126
OpenAlexW2337274641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.